[{"orgOrder":0,"company":"Laboratorios Silanes","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"MEXICO","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Laboratorios Silanes","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Laboratorios Silanes \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Laboratorios Silanes \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Silanes","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"MEXICO","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Laboratorios Silanes","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Silanes \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Laboratorios Silanes \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Silanes","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"MEXICO","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Laboratorios Silanes","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Silanes \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Laboratorios Silanes \/ Undisclosed"},{"orgOrder":0,"company":"Lahore Medical Research Center","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"PAKISTAN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Lahore Medical Research Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lahore Medical Research Center \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Lahore Medical Research Center \/ Undisclosed"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Strides Pharma Science \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Undisclosed"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Strides Pharma Science \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Undisclosed"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Strides Pharma Science \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Undisclosed"},{"orgOrder":0,"company":"Strides Pharma Science","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"||Cyclooxygenase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Strides Pharma Science","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Strides Pharma Science \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Strides Pharma Science \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"||Cyclooxygenase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Granules India Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Granules India Limited \/ Undisclosed"},{"orgOrder":0,"company":"Overseas Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Phase I","graph3":"Overseas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Overseas Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Overseas Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Alkem Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"||Cyclooxygenase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Alkem Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Alkem Laboratories \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Alkem Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"||Cyclooxygenase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Aurobindo Pharma Limited","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Aurobindo Pharma Limited \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Aurobindo Pharma Limited \/ Undisclosed"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"||Cyclooxygenase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Lupin Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Overseas Pharma","sponsor":"Virginia Contract Research Organization","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"INDIA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Overseas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet, Sustained Release","sponsorNew":"Overseas Pharma \/ Virginia Contract Research Organization","highestDevelopmentStatusID":"10","companyTruncated":"Overseas Pharma \/ Virginia Contract Research Organization"},{"orgOrder":0,"company":"Overseas Pharma","sponsor":"Kangqi Medical Technology","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Phase I","graph3":"Overseas Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Overseas Pharma \/ Kangqi Medical Technology","highestDevelopmentStatusID":"6","companyTruncated":"Overseas Pharma \/ Kangqi Medical Technology"},{"orgOrder":0,"company":"Reckitt Benckiser","sponsor":"Premier Research Group","pharmaFlowCategory":"DU","therapeuticArea":"Dental and Oral Health","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Dental and Oral Health","graph2":"Phase III","graph3":"Reckitt Benckiser","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dental & Oral Health","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Reckitt Benckiser \/ Premier Research Group","highestDevelopmentStatusID":"10","companyTruncated":"Reckitt Benckiser \/ Premier Research Group"},{"orgOrder":0,"company":"Haleon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Phase I","graph3":"Haleon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Haleon \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Haleon \/ Undisclosed"},{"orgOrder":0,"company":"Haleon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Phase I","graph3":"Haleon","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Gel","sponsorNew":"Haleon \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Haleon \/ Undisclosed"},{"orgOrder":0,"company":"Endo International","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"IRELAND","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"||Cyclooxygenase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Endo International","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Endo International \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Endo International \/ Undisclosed"},{"orgOrder":0,"company":"Kings College London","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Kings College London","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kings College London \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Kings College London \/ Undisclosed"},{"orgOrder":0,"company":"Kings College London","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Kings College London","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kings College London \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Kings College London \/ Undisclosed"},{"orgOrder":0,"company":"Berlin Chemie","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Berlin Chemie","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Berlin Chemie \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Berlin Chemie \/ Undisclosed"},{"orgOrder":0,"company":"Humanis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"TURKEY","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Phase I","graph3":"Humanis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Humanis \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Humanis \/ Undisclosed"},{"orgOrder":0,"company":"IWK Health Centre","sponsor":"BC Children's Hospital Research Institute | CHU de Quebec-Universite Laval | Sunnybrook Health Sciences Centre | Mount Sinai Hospital, Canada | Sharp Mary Birch Hospital for Women & Newborns | Canadian Institutes of Health Research | Dalhousie Medical Res","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase III","graph3":"IWK Health Centre","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"IWK Health Centre \/ BC Children's Hospital Research Institute | CHU de Quebec-Universite Laval | Sunnybrook Health Sciences Centre | Mount Sinai Hospital, Canada | Sharp Mary Birch Hospital for Women & Newborns | Canadian Institutes of Health Research | Dalhousie Medical Res","highestDevelopmentStatusID":"10","companyTruncated":"IWK Health Centre \/ BC Children's Hospital Research Institute | CHU de Quebec-Universite Laval | Sunnybrook Health Sciences Centre | Mount Sinai Hospital, Canada | Sharp Mary Birch Hospital for Women & Newborns | Canadian Institutes of Health Research | Dalhousie Medical Res"},{"orgOrder":0,"company":"QC Kinetix LLC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Musculoskeletal","graph2":"Phase I\/ Phase II","graph3":"QC Kinetix LLC","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"QC Kinetix LLC \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"QC Kinetix LLC \/ Undisclosed"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cumberland Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cumberland Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Cumberland Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cumberland Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Medolife","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Medolife","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Medolife \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Medolife \/ Undisclosed"},{"orgOrder":0,"company":"AiPing Pharmaceutical Inc","sponsor":"ECI Pharmaceuticals LLC","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Agreement","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Approved FDF","graph3":"AiPing Pharmaceutical Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"AiPing Pharmaceutical Inc \/ ECI Pharmaceuticals LLC","highestDevelopmentStatusID":"15","companyTruncated":"AiPing Pharmaceutical Inc \/ ECI Pharmaceuticals LLC"},{"orgOrder":0,"company":"Cumberland Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Immunology","graph2":"Approved FDF","graph3":"Cumberland Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Cumberland Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Cumberland Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Undisclosed","graph2":"Phase III","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hackensack Meridian Health \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Hackensack Meridian Health \/ Undisclosed"},{"orgOrder":0,"company":"Hackensack Meridian Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Hackensack Meridian Health","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hackensack Meridian Health \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Hackensack Meridian Health \/ Undisclosed"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"McMaster University | Hamilton Academic Health Sciences Organization","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CANADA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Hamilton Health Sciences \/ McMaster University | Hamilton Academic Health Sciences Organization","highestDevelopmentStatusID":"8","companyTruncated":"Hamilton Health Sciences \/ McMaster University | Hamilton Academic Health Sciences Organization"},{"orgOrder":0,"company":"Apsen Farmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BRAZIL","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Apsen Farmaceutica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Apsen Farmaceutica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apsen Farmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Apsen Farmaceutica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BRAZIL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Phase II","graph3":"Apsen Farmaceutica","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apsen Farmaceutica \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apsen Farmaceutica \/ Undisclosed"},{"orgOrder":0,"company":"Brainfarma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"BRAZIL","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Musculoskeletal","graph2":"Phase III","graph3":"Brainfarma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Gel","sponsorNew":"Brainfarma \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Brainfarma \/ Undisclosed"},{"orgOrder":0,"company":"Laboratorios Qu\u00edmica Luar","sponsor":"National Council of Scientific Research, Argentina | Centro de Excelencia C\u00f3rdoba","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ARGENTINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Laboratorios Qu\u00edmica Luar","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Laboratorios Qu\u00edmica Luar \/ National Council of Scientific Research, Argentina | Centro de Excelencia C\u00f3rdoba","highestDevelopmentStatusID":"1","companyTruncated":"Laboratorios Qu\u00edmica Luar \/ National Council of Scientific Research, Argentina | Centro de Excelencia C\u00f3rdoba"},{"orgOrder":0,"company":"Undisclosed","sponsor":"Genome & Company","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Miscellaneous","year":"2024","type":"Acquisition","leadProduct":"Ibuprofen","moa":"Cyclooxygenase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Undisclosed","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Undisclosed \/ Genome & Company","highestDevelopmentStatusID":"15","companyTruncated":"Undisclosed \/ Genome & Company"},{"orgOrder":0,"company":"Salus Pharmaceuticals","sponsor":"AFT Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"INDIA","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"Paracetamol","moa":"||Anandamide amidohydrolase | Cyclooxygenase | Vanilloid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Salus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Salus Pharmaceuticals \/ AFT Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Salus Pharmaceuticals \/ AFT Pharmaceuticals"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"KBC Securities","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Miscellaneous","year":"2020","type":"Public Offering","leadProduct":"Paracetamol","moa":"||Anandamide amidohydrolase | Cyclooxygenase | Vanilloid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hyloris Pharmaceuticals \/ KBC Securities","highestDevelopmentStatusID":"15","companyTruncated":"Hyloris Pharmaceuticals \/ KBC Securities"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Paracetamol","moa":"||Anandamide amidohydrolase | Cyclooxygenase | Vanilloid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hyloris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hyloris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Paracetamol","moa":"||Anandamide amidohydrolase | Cyclooxygenase | Vanilloid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hyloris Pharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Hyloris Pharmaceuticals \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Paracetamol","moa":"||Anandamide amidohydrolase | Cyclooxygenase | Vanilloid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hyloris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hyloris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"BELGIUM","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Paracetamol","moa":"||Anandamide amidohydrolase | Cyclooxygenase | Vanilloid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Hyloris Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Hyloris Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hyloris Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Hikma Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Paracetamol","moa":"||Anandamide amidohydrolase | Cyclooxygenase | Vanilloid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Hikma Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hikma Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Hikma Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Perrigo Company plc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"IRELAND","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Paracetamol","moa":"||Anandamide amidohydrolase | Cyclooxygenase | Vanilloid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Perrigo Company plc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Perrigo Company plc \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Perrigo Company plc \/ Undisclosed"},{"orgOrder":0,"company":"Reckitt Benckiser","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Paracetamol","moa":"||Anandamide amidohydrolase | Cyclooxygenase | Vanilloid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Reckitt Benckiser","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Reckitt Benckiser \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Reckitt Benckiser \/ Undisclosed"},{"orgOrder":0,"company":"AFT Pharmaceuticals","sponsor":"Hikma Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"NEW ZEALAND","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Paracetamol","moa":"||Anandamide amidohydrolase | Cyclooxygenase | Vanilloid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"AFT Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AFT Pharmaceuticals \/ Hikma Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"AFT Pharmaceuticals \/ Hikma Pharmaceuticals"},{"orgOrder":0,"company":"Alter Pharma group","sponsor":"Hyloris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"COSTA RICA","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Paracetamol","moa":"||Anandamide amidohydrolase | Cyclooxygenase | Vanilloid receptor","graph1":"Neurology","graph2":"Approved FDF","graph3":"Alter Pharma group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alter Pharma group \/ Hyloris Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Alter Pharma group \/ Hyloris Pharmaceuticals"}]
Find Clinical Drug Pipeline Developments & Deals for Midol
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
Synergice, a Strides Pharma initiative, is a new gen B2B platform for diverse portofolio needs.
